With Transcatheter Aortic Valve Replacement (TAVR) revolutionizing the treatment of high-surgical risk patients with severe aortic stenosis, Transcatheter Mitral Valve Replacement (TMVR) is slowly emerging as an off-label therapy for severe mitral valve disease. A case of 70-year-old female with recurrent history of congestive heart failure has been described. This case demonstrates the simultaneous TAVR and off-label VIV TMVR is a reasonable alternative for highrisk surgical patients with stenotic native and failing bioprosthetic valves.
Tanya Doctorian, Daniel Serna, Blanding Jones, Arti Choure1, Ramdas Pai4, Eric Chou1 and William Mosley II1
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2018 All rights reserved. iMedPub LTD Last revised : June 18, 2018